Radiopharm Theranostics Reports Encouraging Initial Phase 1 Data for 177Lu-RAD202 in HER2+ Solid Tumors

summarizeSummary

Radiopharm Theranostics announced positive initial findings from its Phase 1 HEAT trial for 177Lu-RAD202, demonstrating encouraging tumor uptake and a favorable safety profile in HER2+ solid tumors, supporting continued dose escalation.

check_boxKey Events

• Positive Phase 1 Initial Findings

  177Lu-RAD202 demonstrated encouraging tumor uptake and a favorable safety profile in the lowest dose cohort of the HEAT trial for HER2+ solid tumors.

• Favorable Safety Profile

  No dose-limiting toxicities or treatment discontinuations due to adverse events were observed, with organ-level radiation doses within clinically acceptable ranges.

• Dose Escalation Approved

  The Data Safety and Monitoring Committee (DSMC) approved advancing 177Lu-RAD202 to the next highest dose at 130 mCi, following these positive initial results. This advancement was previously announced on April 8, 2026.

• AACR Presentation

  These first-in-human safety, biodistribution, dosimetry, and tumor uptake findings were presented at the American Association for Cancer Research (AACR) Annual Meeting 2026.

auto_awesomeAnalysis

This 6-K filing provides crucial early clinical data for Radiopharm Theranostics' 177Lu-RAD202, a HER2-targeted radiopharmaceutical therapy. The positive safety profile and encouraging tumor uptake observed in the lowest dose cohort are significant milestones for a clinical-stage company. The Data Safety and Monitoring Committee's approval to advance to a higher dose level, which was previously announced on April 8, 2026, is now supported by these initial findings. These results, presented at AACR, de-risk the program and provide a foundation for future development, potentially attracting further investor interest.